Allegan’s Perrigo will get new corporate leadership in a week, and he brings a wealth of knowledge in the pharmaceutical business to the healthcare products firm.
Perrigo Company, which is a leading global provider of “Quality Affordable Healthcare Products,” has announced today the appointment of Uwe Röhrhoff as Chief Executive Officer. He new role is effective January 15, 2018, following the retirement of John T. Hendrickson.
Perrigo Chairman Laurie Brlas says, “The Board of Directors is excited to announce the appointment of Uwe as President and Chief Executive Officer. He is an experienced, well-respected and successful CEO. Uwe brings a strong track record of operational excellence, strategic growth, and healthcare supply chain management.”
Brlas says, “As the CEO of Gerresheimer AG, a publicly-traded international manufacturer for the global pharmaceutical and healthcare industries, Uwe’s transformative strategic vision and focus on operational excellence enhanced the company’s leading market positions and created significant value for shareholders of approximately 225-percent in total shareholder return as CEO.” She adds, “We are confident that his leadership style and industry, financial and operational expertise are the right fit for Perrigo. We are grateful to John for his passionate leadership and contributions to the Company over the past 28 years. John has been a trusted leader, a great colleague, and a friend to many, and we value his continued guidance as Uwe transitions into his new role.”
Röhrhoff has more than 25 years of experience with Gerresheimer AG, a leading global manufacturer of pharmaceutical packaging products and medical devices for storage, dosage and safe administration of drugs that generated approximately 1.4 billion euros in revenue in 2016.
He began his career with Gerresheimer AG in 1991, steadily advancing within the organization to serve in a number of key leadership roles in Europe and North America, and was appointed to build out the Company’s business in the United States (1996-1998) and head the American subsidiary Gerresheimer Glass Inc. (2001-2010). He also served as an executive board member (2003-2017), responsible for two of the company’s three business units, and CEO (2010-2017) of Gerresheimer AG until his retirement in August 2017.
Röhrhoff, brings with him an extensive operational track record. He led an organization that included 36 manufacturing facilities across 14 countries, delivering products to 1,500 customers, including the 10 largest global pharmaceutical companies, in nearly 100 countries. He was instrumental in determining Gerresheimer AG’s strategic focus, transforming and reshaping the corporate portfolio and delivering on operational projects.
Röhrhoff serves as Audit Committee Chairman on the Board of Directors of Catalent, Inc., a global provider of drug delivery technology and development solutions for drugs, biologics and consumer health products. He is also Deputy Chairman of Klöckner&Co SE, one of the world’s largest producer-independent steel and metal distributors. As a result of his new role, Röhrhoff plans to step down from both boards. He earned a business administration degree from the University of Cologne.
Commenting on the opportunities ahead for Perrigo, Röhrhoff says, “I am excited for the opportunity at Perrigo. I look forward to working with Perrigo’s experienced management team, who have been instrumental in positioning the Company’s consumer OTC and prescription pharmaceutical businesses to capitalize on current trends in the market.” Rohrhoff adds, “I have long admired Perrigo’s operational excellence and its mission to deliver high-quality, affordable healthcare products that improve the lives of patients and families. I see great opportunity to leverage the Company’s unique asset base and to lead its talented employees to deliver enhanced value for shareholders. Perrigo’s core values resonate with me deeply, and I look forward to leading this organization into its next stage of evolution.”
Hendrickson will resign as CEO and board member on January 15, 2018 and will remain with the Company until March 15, 2018 to ensure a smooth and successful transition.
Perrigo Company was founded in Allegan in 1887 as a packager of home remedies, and has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world’s largest manufacturers of over-the-counter healthcare products and suppliers of infant formulas for the store brand market. The company is also a leading provider of branded over the counter products throughout Europe and the U.S., as well as a leading producer of “extended topical” prescription drugs.
